A large number of pharmaceutical companies have positive results, and the traditional Chinese medicine sector has performed well

Recently, pharmaceutical companies have successively released 2021 performance forecasts.
As of January 16, 33 A-share listed pharmaceutical and biological companies have released 2021 performance forecasts
.
According to the forecast, 80% of pharmaceutical companies are expected to have positive results in 2021, of which 17 are expected to increase, 7 are slightly increased, and 3 are turning losses
.
For example, on January 12, Tigermed disclosed the 2021 annual performance forecast, saying that in 2021, Tigermed's expected net profit attributable to shareholders of listed companies is about 2.
625 billion to 3.
027 billion yuan, a year-on-year increase of 50%-73%; at the same time, It is estimated that the net profit attributable to the parent after deduction is about 1.
133 billion yuan to 1.
324 billion yuan, a year-on-year increase of 60%-87%
.
Although Tigermed is a pharmaceutical company, half of its profits come from investment
.
It is reported that the financial assets invested by Tigermed are mainly biopharmaceuticals, medical devices and other companies related to the company's main business and medical and health professional investment funds.
The gains from changes in fair value recognized by business-related companies in accordance with the new financial instrument standards ranged from RMB 1.
2 billion to RMB 1.
6 billion
.
On January 10, Poinsettia announced that it is expected that the net profit before non-deduction of poinsettia will be 293 million-361 million yuan in 2021, a year-on-year increase of 30%-60%; the net profit after non-deduction is expected to be 197 million-240 million yuan.
Yuan, a year-on-year increase of 35%-65%
.
Regarding the reasons for the changes in performance, Poinsettia said that the revenue growth of its leading products, Clindamycin Hydrochloride Palmitate Dispersible Tablets, Qinxiang Qingjie Oral Liquid, Fuganlin Oral Liquid, and new products contributed to the company's revenue
.
During the reporting period, the company obtained a total of 12 drug (re) registration approvals for 10 products such as ambroxol hydrochloride drops and levocetirizine hydrochloride oral drops.
Actively contribute
.
In addition, the innovative R&D project of Poinsettia has been gradually implemented, and the strategic transformation is being accelerated
.
According to the 2021 annual performance forecast released by Yan'an Bikang Pharmaceutical recently, the company's net profit in 2021 will turn from losses to profits, with a profit of 950 million to 1 billion yuan, a year-on-year increase of about 188.
72% - 193.
39%
.
It is worth noting that in 2021, the Chinese medicine sector is expected to increase its net profit by a large margin
.
For example, after nearly two years of adjustment and integration, Conba's profitability has been improved.
According to the announcement released by Conba on January 14, Conba is expected to achieve revenue of about 6.
18 billion yuan in 2021, a year-on-year increase of 4.
6%.
; Net profit attributable to shareholders of listed companies was 1.
9283 billion yuan to 2.
1533 billion yuan, a year-on-year increase of 325%-375%
.
According to the 2021 annual performance forecast released by Teyi Pharmaceutical on January 12, in 2021, Teyi Pharmaceutical is expected to have a net profit of 120 million yuan to 150 million yuan, a year-on-year increase of 173.
87% -242.
34%
.
Regarding the growth in performance, Teyi Pharmaceutical stated that during the reporting period, the company's business basically returned to normal levels, and the sales revenue, especially the sales of the core product "Teyi" brand Zhikebao tablets, recovered well.
At the same time, it optimized the product structure and strengthened the brand.
The construction also showed better results for the company
.
In addition, Zuoli Pharmaceutical expects that the net profit attributable to shareholders of listed companies in 2021 will increase by 91.
44% to 110.
58% year-on-year, ranging from 170 million yuan to 187 million yuan
.
Regarding the reasons for the change in performance, Zuoli Pharmaceutical stated that in 2021, based on the three core products of Wuling Capsule, Bailing Tablet and Lingze Tablet, which will be included in the National Essential Drugs List, the operating income has achieved rapid growth.
Market expansion and precipitation have also achieved certain results, and operating income has increased over the same period of the previous year
.
According to the industry, the outstanding performance of the traditional Chinese medicine sector is mainly due to the support of policies
.
At the same time, in recent purchases with volume, the average decline of traditional Chinese medicine products is lower than that of chemical drugs, and the approval of traditional Chinese medicines has also been liberalized in recent years
.
It is understood that in addition to the traditional Chinese medicine sector, the performance of in vitro testing companies in 2021 is also relatively bright
.
Rejing Bio expects its net profit in 2021 to increase by 1684.
65% to 1996.
97% year-on-year, ranging from 2 billion to 2.
35 billion yuan; Mingde Bio expects its net profit in 2021 to increase by 177.
23% to 219.
88% year-on-year, ranging from 1.
3 billion to 1.
5 billion yuan; Orient Bio expects that its net profit in 2021 will increase by 181.
45% to 205.
31% year-on-year, ranging from 4.
72 billion to 5.
12 billion yuan; Kaipu Bio expects its net profit in 2021 to increase by 120.
59% to 137.
14% year-on-year, ranging from 800 million to 860 million yuan
.